Paired analysis of the pre- and post-progression samples showed a significant increase in PD-L1 expression in tumor samples after EGFRTKI treatment resistance, especially for T790M-negative patients, but they were unsure whether increased PD-L1 expression could provide a survival benefit for patients resistant to EGFR-TKIs treatment. This evidence concerns the gene EGFR and neoplasm.